RemeGen Co (HKSE:09995) Cash And Cash Equivalents : HK$811 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Cash And Cash Equivalents?

RemeGen Co's quarterly cash and cash equivalents declined from Dec. 2023 (HK$794.69 Mil) to Jun. 2024 (HK$724.86 Mil) but then increased from Jun. 2024 (HK$724.86 Mil) to Dec. 2024 (HK$810.93 Mil).

RemeGen Co's annual cash and cash equivalents declined from Dec. 2022 (HK$2,310.68 Mil) to Dec. 2023 (HK$794.69 Mil) but then increased from Dec. 2023 (HK$794.69 Mil) to Dec. 2024 (HK$810.93 Mil).

RemeGen Co Cash And Cash Equivalents Historical Data

The historical data trend for RemeGen Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Cash And Cash Equivalents Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

3,281.90

2,151.17

2,310.68

794.69

810.93

RemeGen Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial								2,310.68	1,224.66	794.69	724.86	810.93

RemeGen Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

RemeGen Co (HKSE:09995) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

RemeGen Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

https://www.remegen.com

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.

Executives

I-nova Limited	2101 Beneficial owner
Yantai Rongda Venture Capital Center (limited Partnership)	2103 Interests held jointly with another person
Yang Minhua	2103 Interests held jointly with another person
Xiong Xiaobin	2103 Interests held jointly with another person
Wen Qingkai	2103 Interests held jointly with another person
Deng Yong	2103 Interests held jointly with another person
Fang Jianmin	2103 Interests held jointly with another person
Lin Jian	2103 Interests held jointly with another person
Rongchang Holding Group Ltd.	2103 Interests held jointly with another person
Wang Liqiang	2103 Interests held jointly with another person
Wang Weidong	2201 Interest of corporation controlled by you
Wang Xudong	2103 Interests held jointly with another person
Wei Jianliang	2103 Interests held jointly with another person
Morgan Stanley	2201 Interest of corporation controlled by you
Allianz Se	2201 Interest of corporation controlled by you

RemeGen Co Headlines

No Headlines